Safety and Pharmacokinetics of Oleylphosphocholine (OlPC), Administered Orally in Healthy Adults: A Phase 1, Single Center, Open-label, Staggered, Dose-escalation Trial
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Oleylphosphocholine (Primary)
- Indications Chagas disease; Cryptosporidiosis; Mycoses
- Focus Adverse reactions
- 07 Mar 2024 Status changed from recruiting to discontinued due to change in the risk-benefit ratio.
- 05 Jan 2024 Planned End Date changed from 31 Jan 2024 to 30 Apr 2024.
- 05 Jan 2024 Planned primary completion date changed from 31 Oct 2023 to 30 Apr 2024.